Healthcare / BiotechnologyNasdaqGM
$26.94
+0.07 (+0.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-89.7M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-192.3%
↓Gross Margin
N/A
•Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-183.4M · FCF $-153.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | — | — | — | — | — | — | $12.7M | $16.1M | $8.4M | $1.5M | $2.1M | — | — | — |
| Net Income | $-183.4M | $-183.4M | $-126.6M | $-92.9M | $-82.3M | $-46.2M | $-29.1M | $-20.8M | $-15.8M | $-18.6M | $-11.4M | $-24.8M | $-13.4M | $-5.7M |
| EBITDA | $-173.3M | $-173.3M | $-125.8M | $-94.4M | $-80.7M | $-57.4M | $-40.0M | $-29.4M | $-18.5M | $-22.3M | $-15.1M | $-20.9M | $-11.6M | $-5.2M |
| EPS | -3.69 | -3.69 | -3.44 | -3.33 | -3.36 | -2.42 | -1.64 | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | -319.4% | -184.9% | -222.8% | -1485.3% | -711.7% | — | — | — |
| Net Margin | — | — | — | — | — | — | -229.4% | -129.1% | -188.3% | -1236.9% | -536.1% | — | — | — |
| Balance Sheet | ||||||||||||||
| Debt/Equity | 0.07 | 0.07 | 0.04 | 0.05 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-153.8M | $-153.8M | $-89.7M | $-76.5M | $-79.1M | $-30.3M | $-45.0M | $-37.4M | $9.1M | $-23.8M | $-13.2M | — | — | — |
| Returns | ||||||||||||||
| ROE | -192.3% | -192.3% | -61.3% | -57.7% | — | -18.0% | -34.8% | -21.5% | -58.0% | -59.4% | 30.8% | -50.4% | 30.2% | 16.8% |
| Valuation | ||||||||||||||
| P/B | 7.05 | 7.05 | 2.16 | 1.67 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||
| Revenue Growth | — | — | — | — | — | — | -21.3% | 92.1% | 458.1% | -29.5% | — | — | — | — |
| EPS Growth | -7.3% | -7.3% | -3.3% | 0.9% | — | -47.6% | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+128.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.44 → -3.69
Residual
+128.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.